JUNS - JUPITER NEUROSCIENCES, INC.


0.5752
0.026   4.572%

Share volume: 18,252
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%

$0.55
0.03
0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
25%
Profitability 0%
Dept financing 50%
Liquidity 0%
Performance 50%
Company vs Stock growth
vs
Performance
5 Days
-2.01%
1 Month
-13.61%
3 Months
-93.27%
6 Months
-89.52%
1 Year
-89.52%
2 Year
-89.52%
Key data
Stock price
$0.58
P/E Ratio 
N/A
DAY RANGE
$0.54 - $0.59
EPS 
-$0.09
52 WEEK RANGE
$0.53 - $19.51
52 WEEK CHANGE
-$89.52
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
-7.57
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$78,825
AVERAGE 30 VOLUME 
$105,389
Company detail
CEO: Christer Rosén
Region: US
Website: jupiterneurosciences.com
Employees: 4
IPO year: 2024
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Jupiter Neurosciences, Inc. is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The Company incorporated in Delaware in January 2016. The Company has developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation. The product candidate, called JOTROL™, has many potential indications of use for rare diseases, which of we primarily are targeting Mucopolysaccharidoses Type 1, Friedreich’s Ataxia, and MELAS and with ALS in an earlier development stage. We are currently incorporated and in good standing in the State of Delaware. Our principal executive offices are located at 1001 North US Hwy 1, Suite 504, Jupiter, Florida.

Recent news
loading